Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysisScot A. Niglio, Matthew D. Galsky, Rachel Jia et al.|European Urology|2019Cited by 109
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancerAlberto Martini, Matthew D. Galsky, Lauren C. Harshman et al.|Cancer|2019Cited by 47
Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinomaAlberto Martini, John P. Sfakianos, Jorge Daza et al.|British Journal of Urology|2019Cited by 44
The obesity paradox in metastatic castration-resistant prostate cancerAlberto Martini, Matthew D. Galsky, Qainat N. Shah et al.|Prostate Cancer and Prostatic Diseases|2021Cited by 33
Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer DatabaseJohn Pfail, John P. Sfakianos, François Audenet et al.|Bladder Cancer|2020Cited by 17